Study wrapper · #535
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
Editor's note
This is a 12-week randomized, placebo-controlled trial (53 participants) testing whether tesamorelin worsens insulin sensitivity or glycemic control in people with type 2 diabetes — a valuable safety question, since growth-hormone therapy can impair glucose handling, and notably a non-HIV population. Researchers reported no significant differences between placebo and tesamorelin (1 mg or 2 mg) in insulin response, fasting glucose, HbA1c, or overall diabetes control, and no discontinuations for loss of diabetes control; total and non-HDL cholesterol decreased modestly in the 2 mg group. The trial is small and short, but the randomized placebo-controlled design directly addresses a specific safety concern. It supports the position that, over 12 weeks, tesamorelin was not associated with worsened glucose control in this diabetic population.
Plain-language abstract
Because growth hormone can raise blood sugar, researchers ran a 12-week randomized, placebo-controlled trial in 53 people with type 2 diabetes to check whether tesamorelin — which prompts the body to release its own growth hormone — would worsen blood-sugar control. Participants received placebo or one of two tesamorelin doses (1 mg or 2 mg daily). After 12 weeks, there were no meaningful differences between groups in the body's insulin response, fasting blood sugar, long-term sugar control (HbA1c), or changes to diabetes medications, and no one dropped out because their diabetes worsened. The 2 mg group had a small drop in total and non-HDL cholesterol. The authors conclude that, over this period, tesamorelin did not alter insulin response or blood-sugar control in people with type 2 diabetes. The study was small and short, but it directly tested a specific safety concern.